Press Releases | ClavystBio

Press Releases

14 Aug 2026

Portfolio

IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics

04 Aug 2026

Portfolio

Cirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional Financing

29 Jun 2026

Portfolio

Biobot Surgical Raises $20 Million led by ClavystBio and supported by ZIG Ventures

25 Jun 2026

Portfolio

Globally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment

24 Jun 2026

Portfolio

Respiree Appoints Patty Riskind as Chair of the Board of Directors

16 Jun 2026

Portfolio

Rejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and Launch

16 Jun 2026

Portfolio

Singapore venture creation group 65LAB funds NUS novel biologics project targeting lung diseases

28 Apr 2026

Portfolio

Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer

22 Apr 2026

Portfolio

Paratus Appoints Alicia Secor as President and Chief Executive Officer; Expands Leadership Team to Support Next Phase of Growth

24 Mar 2026

Portfolio

Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid Tumors

Page

1 2 3 4 5

Stay in the Loop

Sign up to get the latest news on our innovation community and events.

Subscribe Now